The following MDS clinical trials are no longer open to recruitment in the UK.
Clinical trials are expected to recruit patients for a finite period of time. Each trial has an expected recruitment target, i.e. a specific number of patients needed to participate in the trial in order for the results of the trial to be meaningful and answer all of the proposed questions. Once this target is achieved, the trial is closed to recruitment and the data obtained from the trial is analysed and interpreted. It can take several months for this analysis to be completed. The final results are often published in international journals and/or presented at a scientific meeting.
Please visit the following page for Currently Open MDS Clinical Trials.
Learn more about the latest MDS research
MDS Trials No Longer Recruiting
Name of trial drug: KHK2823 For what level of MDS severity risk: Low Risk or High Risk What subtype of MDS: All types – see specific inclusion criteria Read MoreRead full story
Investigational drugs: Azacitidine and Lenalidomide For what level of MDS severity risk: All What subtype of MDS: All (who relapsed after undergoing an Allogeneic Stem Cell Transplantation); also for Acute Myeloid Leukaemia Read MoreRead full story
Name of trial drug: Novel conditioning regimen: fludarabine/cytarabine/amsacrine/busulphan/ATG (FLAMSA-BU) For what level of MDS severity risk: Intermediate – 2 or High Risk What subtype of MDS: Patients with AML and MDS undergoing reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) Read MoreRead full story
Name of trial drug: Deferasirox For what level of MDS severity risk: Low, or low to moderate What subtype of MDS: All Aims and benefits: This trial will investigate how exactly chelation therapy can affect the health of patients with MDS and iron overload Read MoreRead full story
Name of trial drug: Decitabine For what level of MDS severity risk: Intermediate 2 or High Risk What subtype of MDS: MDS with 5% or more marrow blasts or chronic myelomonocytic leukemia (CMML-2); or AML with 20-30% bone marrow blasts Aims and benefits: This trial investigates whether Decitabine has a good response rate in MDS […]Read full story
Name of trial drug: Deferasirox and Erythropoietin (EPO) For what level of MDS severity risk: Low to Intermediate 1 What subtype of MDS: All Aims and benefits: This trial will assess the impact on hemoglobin, platelets and neutrophil, and iron levels in patients treated with Deferasirox combined with Erythropoietin (compared to Erythropoietin alone) Read MoreRead full story